• Male sex - Age ≥ 50 years at time of enrollment - Symptomatic unilateral inguinal hernia confirmed on physical examination - Hernia visible / confirmed on groin ultrasound - Non-recurrent inguinal hernia (primary hernia only) - Willing and able to provide written informed consent - Able and willing to comply with all protocol-required visits, laboratory assessments, imaging, and follow-up - Willing to use contraception and avoid fathering a child during study participation and for 12 months after last dose - Willing to be counseled regarding vitamin D and calcium supplementation Bone safety mitigation measure per PIND response.

Hernia Characteristics - Scrotal hernia (any) - Bilateral inguinal hernia - Recurrent inguinal hernia (prior repair at same site) Renal & Hepatic - Clinically significant renal dysfunction judged by investigator to increase study risk - Clinically significant hepatic dysfunction at baseline Hematologic ■ Clinically significant baseline hematologic abnormality (including elevated hematocrit or polycythemia) Urologic / Prostate - Symptomatic benign prostatic hyperplasia (BPH) requiring active medical or procedural treatment - Clinically significant untreated prostate disease Skeletal / Bone - Baseline osteoporosis (T-score ≤ -2.5 on DEXA at any site) - Recent fragility fracture (within prior 12 months or as judged by investigator) - Other clinically significant skeletal vulnerability judged to increase risk from estrogen suppression Immunosuppression ■ Active immunosuppression (e.g., systemic corticosteroids, biologic agents, post-transplant regimens) Psychiatric ■ Unstable or uncontrolled psychiatric illness that, in the investigator's judgment, would interfere with safe study participation Reproductive / Fertility ■ Actively pursuing fertility or planning conception during study participation Prior / Concomitant Therapy - Current use of androgen replacement therapy, exogenous estrogen, or other endocrine-active agents that would confound study interpretation - Prior or current use of aromatase inhibitor or selective estrogen receptor modulator / degrader within 6 months of enrollment General ■ Any other clinically significant medical condition, laboratory abnormality, or circumstance that, in the investigator's judgment, would place the participant at unacceptable risk or compromise study integrity